Positive Media Coverage Somewhat Unlikely to Affect Astrazeneca PLC (NYSE:AZN) Share Price

Headlines about Astrazeneca PLC (NYSE:AZN) have trended positive this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Astrazeneca PLC earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.7063595892792 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern’s scoring:

Several equities analysts have recently issued reports on the company. BidaskClub lowered Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Pareto Securities raised Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Morgan Stanley lowered Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Finally, Investec upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Wednesday. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $33.39.

Shares of Astrazeneca PLC (NYSE AZN) opened at 29.08 on Friday. The stock has a market cap of $73.63 billion, a P/E ratio of 19.08 and a beta of 0.74. The company has a 50 day moving average price of $32.47 and a 200-day moving average price of $31.40. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. Astrazeneca PLC also saw some unusual options trading activity on Wednesday. Stock traders acquired 8,259 put options on the company. This represents an increase of approximately 1,510% compared to the typical daily volume of 513 put options.

Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The company had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter in the previous year, the company earned $0.83 EPS. Astrazeneca PLC’s revenue for the quarter was down 9.9% on a year-over-year basis. On average, equities research analysts predict that Astrazeneca PLC will post $1.85 earnings per share for the current year.

The company also recently announced a None dividend, which will be paid on Monday, September 11th. Investors of record on Friday, August 11th will be paid a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio (DPR) is 44.92%.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/08/12/astrazeneca-plc-nyseazn-earning-favorable-news-coverage-study-shows-updated-updated.html.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Insider Buying and Selling by Quarter for Astrazeneca PLC (NYSE:AZN)

What are top analysts saying about Astrazeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Astrazeneca PLC and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit